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Chronic hepatitis C virus (HCV) infection is an emerging global health problem. According to recent estimates, >185 million 
individuals worldwide are living with chronic HCV infection (1). 
Without treatment, between 15% and 30% of individuals with HCV 
will progress to cirrhosis, end-stage liver disease, hepatocellular carcin-
oma and, eventually, death. In fact, HCV is believed to be responsible 
for 350,000 annual deaths globally (1). HCV infection accounts not 
only for an important health and social burden (2), but also for a sig-
nificant economic burden, both for the health system (3-5) and for the 
affected individual (6). Importantly, the economic burden of HCV is 
heavily associated with the treatment of complications associated with 
end-stage liver disease (eg, cirrhosis, hepatocellular carcinoma), while 
viral clearance (ie, sustained virological response [SVR]) has been 
associated with lower costs (5,7,8).
The burden of chronic HCV infection is also substantial in Canada, 
with approximately 0.8% of the Canadian population – nearly 250,000 
individuals – living with HCV in 2007 (9,10). However, this figure is 
likely to be an underestimate of the real prevalence, which could be up 
to 2.8% (11,12). Chronic HCV is the leading indication for liver 
transplantation (13), and modelling studies have projected that, under 
the current status quo scenario, the incidence of HCV-related compli-
cations will continue to rise until at least 2035 (5,10). In fact, a recent 
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BACKGROUND: Hepatitis C virus (HCV) eradication leads to 
reduced morbidity, mortality and transmission. Despite the dispropor-
tionate burden of HCV among sex workers, data regarding the HCV 
care continuum in this population remain negligible. 
METHODS: Using baseline data from an ongoing cohort of women sex 
workers in Vancouver (An Evaluation of Sex Workers’ Health Access, 
January 2010 to August 2013), the authors assessed HCV prevalence 
and engagement in the HCV care continuum within the past year. 
Multivariable logistic regression analyses were used to evaluate associa-
tions with recent (ie, in the past year) HCV testing. 
RESULTS: Among 705 sex workers, 302 (42.8%) were HCV sero-
positive. Of these, 22.5% were previously unaware of their HCV sta-
tus, 41.7% had accessed HCV-related care, 13.9% were offered 
treatment and only 1.0% received treatment. Among 552 HCV-
seronegative sex workers, only one-half (52.9%) reported a recent 
HCV test. In multivariable analysis, women who self-identified as a 
sexual/gender minority (adjusted OR [aOR] 1.89 [95% CI 1.11 to 
3.24]), resided in the inner city drug use epicentre (aOR 3.19 [95%CI 
1.78 to 5.73]) and used injection (aOR 2.00 [95% CI 1.19 to 3.34]) or 
noninjection drugs (aOR 1.95 [95% CI 1.00 to 3.78]) had increased 
odds of undergoing a recent HCV test, while immigrant participants 
(aOR 0.24 [95% CI 0.12 to 0.48]) had decreased odds. 
CONCLUSIONS: Despite a high burden of HCV among sex workers, 
large gaps in the HCV care continuum remain. Particularly concern-
ing are the low access to HCV testing, with one-fifth of women living 
with HCV being previously unaware of their status, and the excep-
tionally low prevalence of HCV treatment. There is a critical need for 
further research to better understand and address barriers to engage in 
the HCV continuum for sex workers. 
Key Words: Hepatitis C; HCV testing; HCV treatment; People who use 
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Les lacunes dans le continuum des soins de 
l’hépatite C chez les travailleuses du sexe de 
Vancouver, en Colombie-Britannique : les 
conséquences sur les tests volontaires de dépistage, 
le traitement et les soins de l’hépatite C
HISTORIQUE : L’éradication du virus de l’hépatite C (VHC) entraîne 
une diminution de la morbidité, de la mortalité et de la transmission de la 
maladie. Malgré le fardeau disproportionné du VHC chez les travailleuses 
du sexe, les données relatives au continuum des soins du VHC demeurent 
négligeables au sein de cette population. 
MÉTHODOLOGIE : Au moyen de données initiales provenant d’une 
cohorte de travailleuses du sexe de Vancouver (une évaluation de l’accès des 
travailleuses du sexe à la santé, de janvier 2010 à août 2013), les auteurs ont 
évalué la prévalence du VHC et la participation au continuum des soins du 
VHC au cours de l’année précédente. Les analyses de régression logistique 
multivariées ont permis d’évaluer les associations avec les récents tests du 
VHC (depuis un an). 
RÉSULTATS : Des 705 travailleuses du sexe, 302 (42,8 %) étaient séroposi-
tives au VHC. De ce nombre, 22,5 % ne le savaient pas auparavant, 41,7 % 
avaient eu accès à des soins liés au VHC, 13,9 % s’étaient fait offrir un 
traitement et seulement 1,0 % avait reçu un traitement. Chez les 552 travail-
leuses du sexe séronégatives au VHC, seulement la moitié (52,9 %) déclarait 
avoir récemment subi un test de dépistage. À l’analyse multivariée, celles qui 
affirmaient faire partie d’une minorité sexuelle ou de genre (RC rajusté [RCr] 
1,89 [95 % IC 1,11 à 3,24]), qui habitaient dans l’épicentre de la consomma-
tion de drogue des quartiers pauvres (RCr 3,19 [95 % IC 1,78 à 5,73]) ou qui 
consommaient des drogues injectables (RCr 2,00 [95 % IC 1,19 à 3,34]) ou 
non injectables (RCr 1,95 [95 % IC 1,00 à 3,78]) étaient plus susceptibles 
d’avoir récemment subi un test de dépistage du VHC, tandis que les partici-
pantes immigrantes (RCr 0,24 [95 % IC 0,12 à 0,48]) l’étaient moins. 
CONCLUSIONS : Malgré le fardeau élevé du VHC chez les travailleuses 
du sexe, d’importantes lacunes persistent dans le continuum des soins du 
VHC. Le faible accès au test de dépistage du VHC est particulièrement 
préoccupant, puisque le cinquième des femmes atteintes ne se savait pas 
infectées. La prévalence exceptionnellement faible de traitement du VHC 
est tout aussi préoccupante. Il est urgent de poursuivre les recherches pour 
mieux comprendre et vaincre les obstacles à la participation des travailleuses 
du sexe au continuum des soins du VHC.
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study from Ontario (2) found HCV to be the infectious disease account-
ing for the greatest loss of health-adjusted life years in the province.
Recent advances in HCV therapeutics have resulted in high success 
rates for all genotypes (>90% to 95% in most scenarios). Newer treat-
ments are markedly more effective, safer, shorter and better tolerated 
(1). Importantly, HCV eradication is associated with up to 90% reduc-
tions in all-cause mortality, risk for developing hepatocellular carcinoma 
and need for liver transplantation (14). Additionally, achieving an SVR 
has a secondary prevention benefit, by eliminating the risk of onward 
transmission of HCV (15,16). In fact, given increasing availability of 
highly curative HCV drugs, and building on lessons from the HIV field 
(17), there have been increasing global calls to consider the implemen-
tation of HCV treatment as a prevention strategy (15,16). However, 
this needs to be tempered by the potential for HCV reinfection. 
A comprehensive HCV treatment and prevention strategy would 
need to meet several criteria to achieve optimal individual- and 
population-level health outcomes (18). Knowledge of HCV status (ie, 
being tested for and diagnosed with HCV) represents a critical first step 
in the HCV cascade of care. However, a substantial proportion of indi-
viduals living with HCV (at least 21% in Canada) remain unaware of 
their HCV status (10,19) and are not connected to care and treatment; 
consequently, they are at risk for poor health outcomes. Collectively, 
these issues highlight the critical importance of access to and uptake of 
HCV treatment, as well as other prevention strategies, particularly 
among key affected populations, to maximize the impact of HCV efforts.
HCV disproportionally affects groups who are under-represented in 
health surveillance and who are underserved by the health system. Sex 
workers, particularly those who are street involved and use injection 
drugs, may be particularly vulnerable to HCV infection (1,20). In addi-
tion, multiple studies show that sex workers face many unique challen-
ges that can severely reduce their access to and uptake of health services. 
These include fear of disclosing sex work or drug use due to criminaliza-
tion and stigmatization, disrespect from health care providers, poor 
quality of care, and lack of women- and sex worker-tailored services, 
among others (21,22). However, and despite the increased vulnerability 
to HCV through dual sex/drug use routes and barriers to health services 
among sex workers, research examining access to HCV testing and care 
among this population remains negligible. Therefore, the aim of the cur-
rent study was to characterize engagement in the HCV continuum of 
care and identify correlates of recent HCV testing among a cohort of 
women sex workers in metropolitan Vancouver, British Columbia.
METHODS
Study design
Data were drawn from An Evaluation of Sex Workers’ Health Access 
(AESHA), an ongoing open prospective cohort of >720 women sex 
workers in metropolitan Vancouver, British Columbia, initiated in 
2010. This study was developed based on community collaborations 
with sex work agencies since 2005 (23) and is monitored by a 
Community Advisory Board encompassing >15 agencies. Eligibility 
criteria for this cohort include age ≥14 years, self-identification as 
women (including male-to-female transgender individuals), and 
having exchanged money for sex in the previous 30 days. Participants 
are recruited through a combination of outreach to outdoor/public 
(eg, streets, alleys), indoor (eg, massage parlours, microbrothels, in-call 
locations) and off-street (eg, online and newspapers advertisements) 
sex work venues across metropolitan Vancouver, using time-location 
sampling (24,25). Sampling and recruitment procedures have been 
described in detail previously (23). 
After providing written informed consent, participants complete 
an interview-administered questionnaire at baseline and every six 
months thereafter, and are offered HIV, HCV and other sexually trans-
mitted infections testing, alongside pre- and post-test counselling. 
The questionnaire collects sociodemographic information, sex work 
patterns, sexual health and intimate partners, violence and trauma, 
drug use patterns, health care services access and utilization (including 
HIV and HCV care), and physical, social and structural characteristics 
of the working and living environment. A trained nurse provides basic 
treatment for sexually transmitted infections onsite, as well as referrals 
to health care services when needed. Participants receive an honor-
arium of $40 at each visit for their time and expertise. The study has 
been approved by the Providence Health Care/University of British 
Columbia Research Ethics Board. 
The current study used cross-sectional baseline data from partici-
pants who enrolled between January 2010 and August 2013.
HCV continuum of care 
Study population: For the analysis characterizing the HCV con-
tinuum of care, only participants with serologically confirmed HCV 
infection (ie, HCV antibody positive) at baseline were included. 
Statistical analysis: Descriptive statistics were used to assess engage-
ment in each step of the HCV continuum of care, including the propor-
tion of: women living with HCV; diagnosed and aware of their infection; 
access to HCV related-care; offered treatment; and received treatment. 
Access to HCV care was evaluated through several questions regarding 
HCV care in the six months before the baseline visit, including whether 
women had received regular blood tests for HCV, had seen an HCV 
specialist, had been offered HCV treatment (including if declined) 
and had been receiving HCV treatment. The total number of HCV 
antibody-positive participants at baseline was used as the denominator 
for all calculations. 
Recent HCV testing 
Study population: The analysis of correlates of recent HCV testing 
was restricted to sex workers who self-reported being HCV-seronegative 
at enrollment or who acquired HCV <1 year before the date of their 
baseline visit.
Primary outcome: The primary outcome of interest for this particular 
analysis was recent HCV testing, defined as self-reporting having 
tested for HCV within the 12 months before the baseline visit. 
Participants who had never tested for HCV or those whose last test 
was >12 months were considered to not have a recent HCV test. 
Explanatory variables: Based on previous studies examining correl-
ates of uptake of HCV and HIV testing among sex workers and other 
vulnerable populations (26-32), a range of individual, contextual 
and social-structural explanatory variables were selected that were 
hypothesized to influence utilization of HCV testing in this particular 
setting. Individual-level factors examined included sociodemographic 
characteristics, and substance use behaviours including age (per year 
older), Aboriginal/Indigenous ancestry (including First Nations, 
Métis and Inuit peoples, yes versus no), international migration status 
(immigrant/migrant versus Canadian born), self-identification as sex-
ual/gender minority (lesbian, gay, bisexual, transgender or two-spirit 
versus heterosexuals), baseline HIV status (positive versus negative), 
heavy alcohol drinking (>4 drinks per day, yes versus no), and any 
Figure 1) Hepatitis C virus (HCV) continuum of care for women sex 
workers living with HCV, Vancouver, British Columbia (n=302). AESHA 
An Evaluation of Sex Workers’ Health Access
HCV care continuum among sex workers
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noninjection or injection drug use (yes versus no). Contextual factors 
evaluated included: current place of residence (residing in the inner 
city drug use epicentre [downtown eastside [DTES] versus elsewhere 
in Vancouver versus being homeless), physical and social features 
of the work environment such as primary place of soliciting clients 
(street/public place versus others, including off-street independent/
self-advertising or off-street indoor venue-based solicitation), servicing 
a higher number of clients (≥10 versus <10 clients/week), inconsistent 
condom use with clients (defined as ‘usually’, ‘sometimes’, ‘occasion-
ally’ or ‘never’ versus ‘always’), client-perpetrated physical or sexual 
violence (yes versus no), involvement in peer support (yes versus no) 
and recent incarceration, defined as having been in detention, prison 
or jail overnight or longer (yes versus no). Also considered were social-
structural barriers to health services, including limited availability 
(defined as limited hours of operation or long wait times) and language 
barriers (yes versus no). Except for the sociodemographic variables, all 
other variables refer to the six-month period before the baseline visit.
Statistical analysis: First, individual-, contextual- and social-structural-
level factors were compared among participants who self-reported 
undergoing a recent HCV test with those who did not. In the bivariate 
analyses, logistic regression was used to analyze the categorical and con-
tinuous variables. Then, to examine the independent factors associated 
with recent HCV testing, a multivariable logistic regression model was 
fitted using an a priori defined model-building approach based on the 
examination of the Akaike information criterion (AIC) and P values. 
A backward stepwise technique was used in the selection of covariates. 
This approach has been used successfully in several studies (26,33). 
Starting with a full model containing all variables associated with the 
outcome at P<0.10 level in bivariate analyses, the AIC of the model is 
noted and the variable with the largest P value is dropped to build a 
reduced model. This iterative process is continued until no variables are 
left. The model with the lowest AIC value is selected as the final model. 
Two-sided P values, and unadjusted and adjusted ORs (aOR) with 95% 
CIs are reported. All statistical analyses were performed using SAS ver-
sion 9.4 (SAS Institute, USA).
RESULTS
HCV continuum of care
Among 705 sex workers who received HCV testing at baseline, 302 
were seropositive for HCV, corresponding to an HCV prevalence of 
42.8%. Among them, the median age was 36 years (interquartile range 
29 to 43 years), slightly more than one-half (51.7%) were of 
Indigenous/Aboriginal ancestry, and one-third identified as a sexual/
gender minority (33.1%). Recent use of noninjection or injection 
drugs was self-reported by 93.1% and 74.5%, respectively. With regard 
to the work environment, the majority (77.8%) were women who 
primarily solicited clients in public spaces. Overall, at baseline, 77.5% 
of participants were aware of their HCV infection, 41.7% reported 
having accessed HCV-related care, 13.9% having been offered treat-
ment and only 1.0% reported receiving treatment (Figure 1).
Recent HCV testing
The present analysis included 552 women sex workers, of whom 420 
(76.1%) self-reported being HCV-seronegative at baseline and an 
additional 132 (23.9%) being newly diagnosed with HCV within one 
year before enrollment. The median age was 34 years (interquartile 
range 27 to 42 years), 183 (33.2%) were of Indigenous/Aboriginal 
ancestry, and 46 (8.3%) were also living with HIV. More than one-
quarter (27.0%) lived in the inner city drug use epicentre, and more 
than one-half primarily solicited clients in public/outdoor settings 
(51.6%). Recent use of noninjection or injection drugs was self-reported 
by 65.6% and 34.4% participants, respectively. In total, 292 (52.9%) 
reported undergoing a recent HCV test (ie, within the past year).
As shown in Table 1, factors positively and statistically significantly 
(ie, P<0.05) associated with recent HCV testing in bivariate analyses 
included being of Aboriginal/Indigenous ancestry, identifying as a sexual/
gender minority, living with HIV, use of injection and noninjection 
Table 1
bivariate logistic regression analyses of factors associated 
with recent hepatitis C virus (HCV) testing among self-
reported HCV-negative female sex workers in Vancouver, 
british Columbia (n=552)
Characteristic
Recent HCV test, n (%)
OR (95% CI) PYes (n=292) No (n=260)
Age, median (IQR) 32.5 (26–41) 35 (29–42) 0.98 (0.97–1.00) 0.079
Sexual/gender minority
   Yes 99 (33.9) 33 (12.7) 3.53 (2.28–5.47) <0.001
   No 193 (66.1) 227 (87.3)
Aboriginal ancestry
   Yes 129 (44.2) 54 (20.8) 3.02 (2.07–4.41) <0.001
   No 163 (55.8) 206 (79.2)
Living with HIV*
   Yes 34 (11.6) 12 (4.6) 2.67 (1.35–5.27) 0.005
   No 257 (88.0) 242 (93.1)
Heavy drinking*
   Yes 9 (3.1) 4 (1.5) 2.02 (0.61–6.63) 0.248
   No 282 (96.6) 253 (97.3)
Non-injection drug use*
   Yes 254 (87.0) 108 (41.5) 9.41 (6.18–14.33) <0.001
   No 38 (13.0) 152 (58.5)
Injection drug use*
   Yes 149 (51.0) 41 (15.8) 5.57 (3.71–8.34) <0.001
   No 143 (49.0) 219 (84.2)
Immigrant to Canada
   Yes 25 (8.6) 142 (54.6) 0.08 (0.05–0.13) <0.001
   No 266 (91.1) 118 (45.4)
Current place of residence* (Vancouver, British Columbia)
   Outside DTES 134 (45.9) 210 (80.8) Reference
   DTES 125 (42.8) 24 (9.2) 8.16 (5.01–13.29) <0.001
   Homelessness 29 (9.9) 21 (8.1) 2.16 (1.19–3.95) 0.012
Primary place of soliciting clients*
   Outdoor/public 199 (68.2) 86 (33.1) 4.33 (3.03–6.19) <0.001
   Indoor/ off-street/
independent
93 (31.8) 174 (66.9)
Higher number of clients*
   Yes (≥10/week) 140 (48.0) 148 (56.9) 0.69 (0.49–0.97) 0.035
   No (<10/week) 146 (50.0) 107 (41.2)
Inconsistent condom use with clients*
   Yes 65 (22.3) 31 (11.9) 2.16 (1.36–3.45) 0.001
   No 219 (75.0) 226 (86.9)
Involvement in peer support*
   Yes 53 (18.2) 22 (8.5) 2.47 (1.46–4.20) 0.001
   No 231 (79.1) 237 (91.2)
Physical/sexual violence by client*
   Yes 84 (28.8) 46 (17.7) 1.88 (1.25–2.82) 0.002
   No 208 (71.2) 214 (82.3)
Recent incarceration*
   Yes 57 (19.5) 19 (7.3) 3.11 (1.79–5.38) <0.001
   No 229 (78.4) 237 (91.2)
Language barrier to health services*
   Yes 3 (1.0) 29 (11.2) 0.08 (0.03–0.28) <0.001
   No 289 (99.0) 231 (88.8)
Availability barrier to health services*
   Yes 112 (38.4) 106 (40.8) 0.90 (0.64–1.27) 0.563
   No 180 (61.6) 154 (59.2)
*Refers to the six-month period before the baseline interview. Column percent-
ages may not necessarily sum to 100% due to missing data or rounding error. 
DTES Downtown eastside; IQR Interquartile range
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drugs, currently residing in the inner city drug use epicentre, or being 
homeless (versus living outside the DTES), primarily soliciting clients 
in public/outdoor spaces, having been exposed to client-perpetrated 
violence, inconsistent condom use with clients, involvement in peer 
support and recent incarceration. In contrast, immigrant women, par-
ticipants with higher number of clients and those reporting language 
barriers to health services had reduced odds of undergoing a recent 
HCV test.
As indicated in Table 2, in multivariable analyses, identifying as a 
sexual/gender minority (aAOR 1.89 [95% CI 1.11 to 3.24]), use of 
injection (aOR 2.00 [95% CI 1.19 to 3.34]) or noninjection drugs 
(aOR 1.95 [95% CI 1.00 to 3.78]) and living in the inner city drug use 
epicentre (versus elsewhere in Vancouver) (aOR 3.19 [95% CI 1.78 to 
5.73]) remained independently and positively statistically significantly 
associated with undergoing a recent HCV test, while immigrant par-
ticipants (aOR 0.24 [95% CI 0.12 to 0.48]) were less likely to have had 
a recent HCV test.
DISCUSSION
To our knowledge, the present study was the first to characterize 
access and uptake along the HCV care continuum among sex work-
ers, a population with disproportionate burden of HCV (1,20). In the 
present analysis, only one-half of the women who self-reported being 
HCV seronegative or previously unaware of their HCV status had been 
tested for HCV in the past year. In addition, among women living with 
HCV, approximately one-quarter were unaware of their HCV status 
before undergoing an HCV test at their baseline visit. Importantly, 
and similar to a previous study of recent HIV testing among women 
sex workers in this setting (26), we found that a number of markers of 
vulnerability were associated with recent HCV testing, including use 
of noninjection and injection drugs, self-identification as a gender/
sexual minority, and living in the inner city drug use epicentre (ie, 
the DTES). In contrast, immigrant participants had reduced odds of 
undergoing a recent HCV test.
A possible explanation to our findings is that to date, voluntary 
HCV screening programs in Canada have mostly used a risk-based 
approach, targeting individuals perceived to be at higher risk for 
HCV infection, including people who use injection drugs, or with 
clinical or laboratory evidence of liver disease (9). It is likely that the 
provincial government-sponsored “HIV Treatment as Prevention” 
efforts (ie, STOP HIV/AIDS®) to scale-up access to HIV testing and 
care, with a particular focus on the inner city DTES community, 
have contributed to increase uptake of HCV testing among these 
vulnerable populations (34,35). However, the high prevalence of 
undiagnosed HCV infection among sex workers found in the present 
analysis suggests that the effectiveness of risk-based testing strategies 
for HCV may be limited. Studies suggest that years of targeted 
screening programs for HCV might have contributed to community 
or health provider perceptions that only certain vulnerable popula-
tions are at-risk of acquiring HCV (eg, people who inject drugs) 
(36,37). Thus, given that HCV testing is only performed nominally, 
this stigma, as well as fear of disclosure of positive results, might pose 
barriers to HCV testing particularly in more underserved and crimin-
alized populations such as women sex workers.
Of particular concern is that in our study, immigrant women were 
less likely to report having a recent HCV test. These results are con-
sistent with previous research from different settings showing that 
migrant and new immigrant populations frequently experience 
enhanced barriers to health services (33,38-40). These barriers 
include limited knowledge on how to navigate the local health sys-
tem, stigma, cultural and language barriers, as well as woman’s immi-
gration legal status, which could result in exclusion from publicly 
funded health insurance. Altogether, these findings highlight the 
need for tailored interventions to facilitate migrant sex workers’ 
access to voluntary testing and other health services, such as peer/sex 
worker-led outreach to connect migrant sex workers to culturally 
appropriate and low-threshold health services. In addition, as lessons 
from successful global initiatives demonstrate, community empower-
ment through sex workers collectivization can play a key role in 
increasing access to health and social services for all sex workers, 
including migrant women (41-43).
Our results also showed that >40% of women sex workers in 
Vancouver had evidence of current/past HCV infection, likely due to 
dual parenteral and sexual routes (44-47). However, and despite this 
high HCV prevalence, fewer than one-half of sex workers living with 
HCV in our study reported being connected to HCV care and almost 
none were receiving treatment. These results are consistent with pre-
vious studies showing extremely low rates of HCV treatment uptake in 
British Columbia, particularly among women (4) and people who use 
illicit drugs (48).
Although not formally evaluated in the current study, determin-
ants of low treatment uptake among this cohort of sex workers may 
reflect a combination of structural and individual barriers to health 
care. Misperceptions of HCV as relatively benign disease, absence of 
symptoms associated with chronic HCV until advanced stages, fear of 
side effects and associated treatment costs have been suggested as 
important individual-level barriers to HCV treatment uptake (49,50). 
For example, a recent study indicated that individuals with chronic 
HCV in British Columbia face substantial out-of-pocket expenses on 
HCV-related health care, even within a publicly funded universal 
health care system. The burden of these costs mostly falls on individ-
uals with lower income, which could play a key role in patients forgo-
ing or delaying treatment until advances stages of liver diseases (6). 
Collectively, these findings suggest an urgent need to explore alterna-
tive mechanisms to facilitate and support engagement in care and to 
ensure equitable access to HCV treatment to vulnerable populations 
including sex workers (4,6).
At the provider and macrostructural level, studies have demon-
strated that stigma and misconceptions among health care providers 
regarding eligibility for HCV treatment of people who use drugs, as well 
as their perception of the clients potential to adhere to the regimen and 
Table 2
Multivariable logistic regression model of factors associated 
with recent hepatitis C virus (HCV) testing among self-
reported HCV-negative female sex workers in Vancouver, 
british Columbia (n=552)*
Variable adjusted OR (95% CI) P
Sexual/gender minority
   Yes versus no 1.89 (1.1–3.24) 0.020
Non-injection drug use†
   Yes versus no 1.95 (1.00–3.78) 0.049
Injection drug use*
   Yes versus no 2.00 (1.19–3.34) 0.008
Immigrant to Canada
   Yes versus no 0.24 (0.12–0.48) <0.001
Current place of residence† (Reference: outside downtown eastside)
   Downtown eastside, Vancouver 3.19 (1.78–5.73) <0.001
   Homelessness 1.03 (0.50–2.12) 0.928
Higher number of clients†
   Yes versus no 0.67 (0.43–1.06) 0.088
Recent incarceration†
   Yes versus no 1.87 (0.95–3.67) 0.069
*Only the final list of variables included in the model with the best overall fit 
(ie, lowest Akaike information criterion value) are shown. Age, Aboriginal ances-
try, HIV status, primary place of soliciting clients, client-perpetrated violence, 
inconsistent condom use by clients, peer support and language barriers to health 
services were included in the full model, but removed in the backwards selection 
approach; †Refers to the six-month period before the baseline interview 
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eventual risk of re-infection represent major barriers to access to 
HCV treatment in this setting (49,51,52). Additionally, Canada’s 
criminalized sex work and drug use environment poses a further chal-
lenge in this regard. In fact, previous studies have shown that poli-
cing practices can play an important role in shaping health care 
access among marginalized populations such as sex workers, people 
who use drugs or transwomen (22,53-55). Accordingly, decriminal-
ization of sex work and drug use could offer an important first step 
toward increasing access to HCV testing and care to these vulnerable 
populations and a critical step for the success of any HCV ‘treatment 
as prevention’ strategy (16,56). For example, decriminalization of sex 
work could facilitate connections to health services of hidden 
migrant sex workers, who primarily work in indoor settings, do not 
disclose their involvement in sex work to friends, families and pro-
viders, and who are often disengaged from care. In addition, improv-
ing access to HCV care will require a combination intervention 
approach, including mobile and culturally competent services, as 
well as harm reduction and addiction management among other 
social-structural interventions (52).
The present study had several limitations. First, due its cross-
sectional design, we were unable to determine temporal and causal 
relationships between the explanatory variables and outcome. Second, 
our sample was not randomly selected and, therefore, the results of the 
present study may not be generalizable to all sex workers in Vancouver 
or to other settings. However, the use of time-location sampling 
(24,25), a strategy known to help achieve representative samples of 
hard-to-reach populations helped to mitigate such potential bias. 
Third, because the data were collected through self-reporting, they 
may have been subject to recall or social-desirability biases. However, 
all interviews were conducted in confidential and safe environments 
by highly experienced interviewers with strong community rapport 
and involvement, facilitating accurate responses. Fourth, due to the 
lack of access to HCV RNA, we were not able to evaluate the number 
of participants with confirmed chronic HCV infection or with SVR. 
However, as studies of the natural history of HCV infection show, up 
to 85% of individuals infected with HCV will progress to chronic 
infection (57,58). In addition, the extremely low HCV treatment 
uptake within this cohort makes SVR a rare event.
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